FDA approved the JAK inhibitor as the first oral medicine for moderate to severe ulcerative colitis, providing Pfizer with fertile new commercial ground for the blockbuster drug.
Pfizer Inc. has secured fertile new commercial ground for its blockbuster rheumatoid arthritis drug Xeljanz (tofactinib) with an expanded US FDA approval in patients with moderately to severely active ulcerative colitis.
FDA approved the janus kinase (JAK) inhibitor Xeljanz for the indication May 30 as expected, following an unanimously positive recommendation...
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
The Belgian drugmaker is boosting its biologics capacity over the pond.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
